Cell surface phenotype and human T lymphotropic virus type 1 antigen expression in 12 T cell lines derived from peripheral blood and cerebrospinal fluid of West Indian, Guyanese and African patients with tropical spastic paraparesis

Gessain, Antoine; Saal, F; Giron, Marie-Lou; Lasneret, J; Lagaye, Sylvie; Gout, Olivier; Sigaux, François; Périès, J.

doi:10.1099/0022-1317-71-2-333

Cited by 49 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference may relate to differences in expression of cell-surface molecules relevant to filtration in HTLV-I-cultured cell lines such as MT-2. 27 In vitro studies have shown that mononuclear cells of patients with HAM showed decreased expression of L-selectin (CD62L) and increased very late activation antigen 4 (VLA-4) (CD49d) levels relative to HTLV carriers and controls. 28 In addition, removal of T lymphocytes may vary according to the percentage of total T cells carrying the provirus, which ranges between 0.1% and 0.3% in the MT-2 "spiking" model and from 0.005% to 100% in the asymptomatic carriers in this study.…”

Section: Htlv-i Removal By Leukocyte Depletion 679mentioning

confidence: 99%

Persistence of HTLV-I in blood components after leukocyte depletion

Pennington

Taylor²,

Sutherland³

et al. 2002

Blood

View full text Add to dashboard Cite

The human T-cell leukemia virus HTLV-I is a transfusion-transmissible retrovirus targeting T lymphocytes for which screening is not currently undertaken in United Kingdom blood donors. The introduction of universal leukocyte depletion (LD) of the United Kingdom blood supply raises the question as to the degree of protection afforded by this procedure against HTLV-I transmission by blood components. HTLV-I viral DNA removal by leukocyte-depleting filters was assessed in units of whole blood and platelets by real-time quantitative polymerase chain reaction (PCR) and by nested PCR for HTLV-I Tax DNA. We examined HTLV-I removal by LD filters using a model system of blood units containing exogenous spiked HTLV-I-positive MT-2 cells at a relevant concentration and whole blood donations from asymptomatic HTLV-I carriers. T-lymphocyte removal was assessed in parallel by measurement of endogenous subset-specific CD3 mRNA. In the MT-2 model system we observed 3.5 log 10 to 4 log 10 removal of HTLV-I Tax DNA by filtration of whole blood and 2 log 10 to 3 log 10 removal across platelet filters with 13 of 16 whole blood and 8 of 8 platelet units still positive after filtration.Despite 3 log 10 to 4 log 10 viral removal, HTLV-I Tax DNA could be detected after whole blood filtration in asymptomatic carriers with viral loads above 10 8 proviral DNA copies/L. T-lymphocyte removal was also between 3.5 log 10 and 4.5 log 10 . HTLV-I provirus removal was incomplete in the model system and in asymptomatic carriers with viral loads greater than 10 8 copies/L. These results suggest that LD alone may not provide complete protection from HTLV-I transmission by transfusion. (Blood. 2002;100:677-681)

show abstract

Section: Htlv-i Removal By Leukocyte Depletion 679mentioning

confidence: 99%

Persistence of HTLV-I in blood components after leukocyte depletion

Pennington

Taylor²,

Sutherland³

et al. 2002

Blood

View full text Add to dashboard Cite

show abstract

“…Fresh cells from TSP/HAM and ATL patients and from HTLV-Iseropositive individuals were obtained from the French West Indies and Japan. The human T-cell line infected with the HTLV-ILAF isolate has been described (18). Total and cytoplasmic RNA was extracted as described (19).…”

Section: Methodsmentioning

confidence: 99%

Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I.

Koralnik

Gessain

Klotman

et al. 1992

Proc. Natl. Acad. Sci. U.S.A.

177

218

View full text Add to dashboard Cite

show abstract

“…One of us had reported the presence of these HTLV-I-associated diseases in patients living in metropolitan France, mainly the Paris area, but originating from French Guiana, and reported the main clinical and immunovirological characteristics (Gessain et al, 1990a(Gessain et al, , 1990b(Gessain et al, , 1990c). An epidemiological study was thus initiated in 1990 to determine the prevalence, incidence, and main clinical characteristics of patients with ATL living in French Guiana .…”

Section: The Origin Of Htlv-i Infection In French Guianamentioning

confidence: 99%

Human T-cell Lymphotropic Virus types I and II (HTLV-I/II) in French Guiana: clinical and molecular epidemiology

Kazanji

Gessain

2003

Cad. Saúde Pública

View full text Add to dashboard Cite

We review here the epidemiological studies performed by our group on human retrovirus HTLV-I and HTLV-II infections and the associated diseases in French Guiana since 1984. French Guiana is an overseas French administrative district located between Key words Retroviridae; HTLV-I; HTLV-II; Genetic Variability; T-cell Leukemia Resumo Os autores apresentam uma revisão dos estudos epidemiológicos realizados pelo seu grupo de pesquisa sobre a infecção pelos vírus T-linfotrópicos humanos tipo I (HTLV-I) e tipo II (HTLV-II) e doenças associadas na Guiana Francesa, desde 1984. A Guiana Francesa é um

show abstract

Cell surface phenotype and human T lymphotropic virus type 1 antigen expression in 12 T cell lines derived from peripheral blood and cerebrospinal fluid of West Indian, Guyanese and African patients with tropical spastic paraparesis

Cited by 49 publications

References 27 publications

Persistence of HTLV-I in blood components after leukocyte depletion

Persistence of HTLV-I in blood components after leukocyte depletion

Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I.

Human T-cell Lymphotropic Virus types I and II (HTLV-I/II) in French Guiana: clinical and molecular epidemiology

Contact Info

Product

Resources

About